Drug news
FDA broadens label of Feraheme to include iron deficiency anemia patients intolerant to oral iron.- Amag Pharma.
AMAG Pharmaceuticals announced that the FDA has approved its application to broaden the existing label for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease (CKD) indication to include all eligible adult Iron Deficiency Anemia (IDA) patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
This sNDA approval immediately doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins